A Phase 1b/2 Dose Escalation and Expansion Study of the Combination of the Bispecific T Cell Redirection Antibodies Talquetamab and Teclistamab in Participants with Relapsed or Refractory Multiple Myeloma

Status

Active, not recruiting

Phases

Phase 1Phase 2

Study type

Interventional

Source

EU CTIS

Registry ID

CTIS2023-503439-16-00

Acronym

64007957MMY1003

Enrollment

Registered

2024-08-14

Start date

2020-12-29

Completion date

Unknown

Last updated

2025-03-10

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Multiple Myeloma

Brief summary

Part 1 and Part 2 •Incidence and severity of DLTs •Incidence and severity of AEs and SAEs, Part 3 •ORR as evaluated by IRC

Interventions

DRUGJNJ-64407564

DRUGDARZALEX 1800 mg solution for injection

DRUGteclistamab

Eligibility

Sex/Gender

All

Age

18 Years to No maximum

Design outcomes

Primary

Measure	Time frame
Part 1 and Part 2 •Incidence and severity of DLTs •Incidence and severity of AEs and SAEs, Part 3 •ORR as evaluated by IRC	—

Countries

Spain

Outcome results

None listed

Source: EU CTIS · Data processed: Feb 4, 2026